Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Raises EUR 84 Million in Private Placement

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
Net proceeds from the transaction will be used to fund the clinical development of MOR208.

MorphoSys AG has announced that it has raised gross proceeds of approximately EUR 84 million in a private placement via an accelerated book building procedure.

MorphoSys issued 1,514,066 new shares from authorized capital to international institutional investors at a price of EUR 55.76 per share, which corresponds to the closing auction price on 18 September 2013, one day prior to the launch of the transaction.

The offering represents approximately 6.3% of the registered pre-transaction share capital and will bring the total number of registered shares after the issuance to 25,669,444, and was multiple times over-subscribed.

The new shares will be admitted to listing on the Frankfurt Stock Exchange following their issuance.

The net proceeds from the transaction will be used by MorphoSys to:
• fund the clinical development of MOR208, our wholly owned anti-CD19 antibody, potentially including an additional phase 2 combination study in chronic lymphocytic leukemia (CLL). MOR208 has completed a phase 1 study in CLL and is in ongoing phase 2 clinical trials in non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL);
• fund the further clinical development of MOR202 (an anti-CD38 antibody currently in a phase 1/2a clinical trial in multiple myeloma), for which MorphoSys has signed a global co-development agreement with Celgene;
• initiate, advance and/or accelerate the development of other proprietary programs, including advancing of pre-clinical or clinical stage assets into later stages of clinical development prior to licensing;
• fund potential acquisitions of new businesses, technologies or products, including MorphoSys's Innovation Capital initiative, that would complement our business or expand our portfolio.

"We are very pleased to announce the successful completion of our placement which we believe reflects the significant progress made at MorphoSys over the past year," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

Dr. Moroney continued, "We have made considerable progress in advancing our pipeline and have announced ground-breaking partnerships with both GlaxoSmithKline and Celgene. The funds we have raised will allow us to further develop our wholly-owned program MOR208, to build on the great potential of MOR202 with our partner Celgene and to invest in other attractive opportunities. We believe MorphoSys is well positioned to build on this positive momentum and to continue to build significant value to shareholders."

Jens Holstein, Chief Financial Officer of MorphoSys AG commented: "In response to the progress the company achieved in recent years and the further promise of our pipeline, we received strong interest from international investors. The offering has allowed us to meet this demand, strengthen our financial position and further enhance trading liquidity. The funds raised will provide additional strategic flexibility as we continue to build the company to create long-term value for our shareholders."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
Flesh-Eating Bacteria Work Together
Scientists recently discovered different strains of deadly flesh-eating bacteria working together to spread infection and they now have a better understanding of the role of the toxins they produce. The discovery could change how the illness and other diseases are treated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!